Genomics Market is most commonly used for the diagnosis of cancer. Recent advancements in personalized medicine and genomics have bought significant transformations in disease management. The growing use of genomics in several clinical trials is reflecting a growing trend. Consequently, The Global Genomics Market is expected to rise at an exponential CAGR of 18.7% between 2018 and 2026. In 2018, the market was valued at US$ 15,888.8 Mn and it is anticipated to reach US$ 62,614.6 Mn by 2026.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941
Leading Players operating in the Genomics Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Thermo Fisher Scientific Inc.
- Oxford Nanopore Technologies
- Danaher
- QIAGEN
- BGI
- IntegraGen
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941
Adoption of Advanced Technologies Renders North America Dominant
From a geographical standpoint, North America dominated the global genomics market in 2018. The region will continue to maintain its dominance through the forecast period. Rapid technological advancements and the presence of sophisticated healthcare infrastructure are driving the market in this region. In 2018, North America was valued at US$ 6,959.3 Mn. The demand for genomic medicine is increasing in North America on account of the rising adoption of personalized medicine and new sequencing technologies.
Europe is expected to display great growth potential owing to the wide availability of funds and the presence of large MNCs. Governments in the U.K. is increasingly making investments in research and development (R&D) activities to favour the expansion of the market in Europe.
The market in Asia Pacific is likely to witness strong growth during the forecast years. The primary factor responsible for the growth is developing healthcare infrastructure. The awareness about genomic technologies is increasing in countries such as India and China, as people in these countries are becoming more aware with regards to the detection of genetic disorders, their treatment and prognosis. All these factors are enabling growth in the market.
Veritas Genetics Launched myGenome to Offer Personalized Services to its Customers
General Electric Company, Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., IntegraGen, QIAGEN, BGI, F. Hoffmann-La Roche Ltd, Danaher, and Illumina, Inc. are some of the leading players in the global genomics market. Among these, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., and Illumina, Inc. are projected to dominate the global market. Strong geographical presence and robust portfolio are factors responsible for their prominent position in the market. Several companies are entering into strategic alliances to better their market position and increase revenue. Bristol Myers Squibb collaborated with Foundation Medicine in March 2017. This collaboration will help the former company to leverage the latter’s molecular information and genomic profiling solutions
The use of genomics is expanding in the medical industry, which is creating growth opportunities for the Global Genomics Market.
Fortune Business Insights in a new report, titled “Genomics: Global Market Analysis, Insights and Forecast, 2019-2026” offers valuable insights into the factors enabling growth in the market.Genomics Market is most commonly used for the diagnosis of cancer.
Some of the companies operating the industry are:Thermo Fisher Scientific Inc.Oxford Nanopore TechnologiesDanaherQIAGENBGIIntegraGenRequest a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941Adoption of Advanced Technologies Renders North America DominantFrom a geographical standpoint, North America dominated the global genomics market in 2018.
Rapid technological advancements and the presence of sophisticated healthcare infrastructure are driving the market in this region.
The demand for genomic medicine is increasing in North America on account of the rising adoption of personalized medicine and new sequencing technologies.Europe is expected to display great growth potential owing to the wide availability of funds and the presence of large MNCs.
Governments in the U.K. is increasingly making investments in research and development (R) activities to favour the expansion of the market in Europe.The market in Asia Pacific is likely to witness strong growth during the forecast years.
Demand for Hepatitis C Treatment Expected to Remain High in North America during 2016-2024According to a recent study conducted by RRI, the global market forhepatitis C treatment is expected to expand at a CAGR of over 13% during the forecast period (2016-2024).
By the end of 2016, market is anticipated to stand at US$ 26.6 and is estimated to surpass US$ 71 Billion by 2024.Factors such as higher per capita healthcare expenditure worldwide and growing prevalence of hepatitis C infections in countries such as U.S. and Canada is expected to drive the global market for global hepatitis C treatment during the forecast period.
On the other hand, expensive drugs for hepatitis C treatment and lack of awareness about hepatitis C infection amongst the people in developing regions across the globe may inhibit the growth of the market during the forecast period.Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114958/Hepatitis-C-Treatment-Market On the basis of drugs, the global market for hepatitis C treatment has been segmented into HCV NS5A inhibitors, HCV protease inhibitors, interferon & antiviral, HCV polymerase inhibitors, and combination therapy.
The segment is expected to expand at a CAGR of over 13% during 2016-2024.On the basis distribution channel, the market has been segmented into online pharmacies, hospital pharmacies and retail pharmacies.
Hospital pharmacy is expected to be the most dominant segment during the forecast period.
The growth of the segment is due to ample stock of hepatitis C treatment drugs with added discount offered by online drug pharmacies.Request Report Discount: https://www.researchreportinsights.com/report/discount/110114958/Hepatitis-C-Treatment-Market On the basis of region, North America is expected to be the leading market for hepatitis C treatment, estimated to account for 45% share by the end of 2016.
"Rising geriatric population and increasing awareness among individuals towards preventive diagnostic tests is providing impetus to the genetic testing market size progressing at a global CAGR of 12.59% during the forecast period of 2019-2025.
" Burgeoning occurrences of intricate diseases such as cancer, cardiovascular disease, and neurological disease, has been persistently stimulating the omnipresent customary diagnostic practices.
And as per the business intelligence report by IndustryARC, rising geriatric population and increasing awareness among individuals towards preventive diagnostic tests is providing impetus to the genetic testing market size progressing at a global CAGR of 12.59% during the forecast period of 2019-2025.The study incorporates all the commercial aspects of the trending genetic testing market ranging from its end-users verticals, applications insights and regional revenue pockets to an imperative competitive landscape and pricing conditions.
An unbiased topography is maintained throughout the report by the analyst via inclusion of challenging aspects pertaining to each segment assisted by effective solutions.The report is titled “Genetic Testing Market: By Type of Testing (Forensic Testing, Newborn Screening, Others); By Method (Molecular, Chromosomal, Biochemical); By Testing Sample (Saliva, Blood, Others); By Industry (Laboratories, Hospitals, Blood Banks, Others) – Forecast (2019 - 2025).” This report covers Genetic Testing Market Size by type and applications, Genetic Testing Market share by top 5 companies and also the market share by start-ups during the forecast period.View Full Table of Contents of Genetic Testing Market:https://www.industryarc.com/Report/15123/genetic-testing-market.htmlReport Price (Single User): US $3850Genetic Testing Market Leading Segments:Accumulating the conclusions by the analyst, it is stated that, North America dominated the genetic testing market by sourcing a substantial 44.71% of global demand in 2018 and is estimated to propel at a significant rate over the forecast period.
Unprecedented development in the incidences of genetic diseases such as cancer, spinal muscular atrophy, turner syndrome and neurofibromatosis in this region is catapulting the market growth.
High demand for genetic testing in North America can also be attributed to the availability of new and advanced diagnostic tests coupled with cutting-edge healthcare facilities and federally subsidized healthcare expenditure.Among different categories of tests involved in the vast ecosystem of genetic testing, the most prominent ones generating significant revenue for the market are forensic testing, carrier testing, diagnostic testing, and newborn screening.
Hepatitis C Drugs Market Competitive Analysis:Leading players in the global hepatitis C drugs market include Gilead Sciences Inc., Johnson & Johnson, GSK, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., and AbbVie Inc.Hepatitis C Drugs Market AnalysisMarket Research Future (MRFR) has released a new report on the global hepatitis C drugs market .
The report provides a complete overview of the market’s historical statistics and growth trajectory, in addition to elaborating on the market’s present statistics and providing detailed purojections regarding the market’s likely growth trajectory over the forecast period from 2016 to 2022.
The global hepatitis C drugs market is expected to exhibit a steady 3.3% CAGR over the forecast period, rising from a valuation of USD 18.7 billion in 2015 to USD 22.7 billion by 2022.The slow CAGR of the global hepatitis C drugs market is due to the steady drop in the number of patients of hepatitis C in developed regions and the increasing prospects of the unorganized herbal medicine industry in emerging regions.Thanks to consistent healthcare advancement initiatives and awareness efforts, the prevalence of hepatitis C has fallen in developed countries over the years and could in fact dip into negatives over the coming years due to the widespread availability of medication and widespread awareness about the disease.
The improving sanitation levels in developed countries have been vital for the drop in the prevalence of hepatitis C, as it has reduced the likelihood of the respective pathogens breeding in large amounts.
The increasing awareness about hygiene and disease prevention in countries such as the U.S., Canada, the UK, France, and Germany is likely to further reduce the prevalence of hepatitis C over the coming years, restraining the growth of the hepatitis C drugs market in developed economies.In emerging regions such as Asia Pacific, hepatitis C is considerably prevalent.
This is likely to be a major restraint for the hepatitis C drugs market over the forecast period.Hepatitis C Drugs Market Segmentation:The global hepatitis C drugs market is segmented on the basis of drug class, medicine system, route of administration, end user, and region.The global hepatitis C drugs market is segmented on the basis of drug class into anti-viral drugs, immuno-modulators, and others.On the basis of medicine system, the global hepatitis C drugs market is segmented into allopathic medicine, alternative medicine, and others.On the basis of route of administration, the hepatitis C drugs market is segmented into oral, injectable, and others.
Oncology Biomarker Market Report published by value market research, it provides a comprehensive market analysis which includes market size, share, value, growth, trends during forecast period 2019-2025 along with strategic development of the key player with their market share.
Further, the market has been bifurcated into sub-segments with regional and country market with in-depth analysis.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the oncology biomarker market include Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Pfizer, Inc. and Qiagen N.V. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Oncology Biomarker Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/oncology-biomarker-market/download-sampleMarket DynamicsGrowing count of the population suffering from various types of cancer has created demand of biomarkers leading to early diagnosis and prognosis of cancer.
Increase funding by government for cancer diagnosis technique and treatment is fueling the market growth.
Owing to a non-invasive method for cancer detection followed by increased cancer awareness is boosting the market growth.
In spite of this advantage, high cost associated with diagnosis is restraining the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis.
Rising healthcare expenditure coupled with the increasing research and developments by companies for reducing the complexities in protein labeling are key factors contributing to high CAGR of Protein Labeling market during the forecast period.the global Protein Labelling market was valued at USD 1396.6 Million in 2018 and is expected to reach USD 3544.9 Million by the year 2026, at a CAGR of 11.8%.
Use of molecular labels in research is very common for purification detection of the labeled proteins and their binding partners.
The companies are focusing on reducing the complexities in the protein labeling process by improving the existing technologies.
The indsutry is witnessing rise in the new product launches and growing adoption of bioengineering technologies in a bid to ramp up the market growth.
Development of the technology to produce advanced dyes that rapidly conjugates with the specific peptides or nucleotidein order to detect their presence and further purification process more accurately is expected to make the process more efficient and will have positive impact on the market.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1879The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers.
